Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 plus tyrosine kinase inhibitor in chronic phase chronic myelogenous leukemia
jRCT2031220084Phase 3Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2022
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic myelogenous leukemia (CML) comparing TM5614 + background tyrosine kinase inhibitor with Placebo + background tyrosine kinase inhibitor (2 arms). Primary endpoint: DMR maintenance rate at 96 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
TM5614
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2031220084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220084.